These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21953178)

  • 1. Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.
    Wehr C; Müller F; Schüler J; Tomann T; Nitschke C; Seismann H; Spillner E; Klingner K; Schneider-Merck T; Binder M; Fiebig HH; Mertelsmann R; Trepel M
    Int J Cancer; 2012 Jul; 131(2):E10-20. PubMed ID: 21953178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor.
    Kondo E; Harashima A; Takabatake T; Takahashi H; Matsuo Y; Yoshino T; Orita K; Akagi T
    Eur J Immunol; 2003 Jan; 33(1):1-11. PubMed ID: 12594826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification.
    Renschler MF; Wada HG; Fok KS; Levy R
    Cancer Res; 1995 Dec; 55(23):5642-7. PubMed ID: 7585648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
    Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
    Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells.
    Mimori K; Kiyokawa N; Taguchi T; Suzuki T; Sekino T; Nakajima H; Saito M; Katagiri YU; Isoyama K; Yamada K; Matsuo Y; Fujimoto J
    Leukemia; 2003 Jun; 17(6):1164-74. PubMed ID: 12764385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved access to CD20 following B cell receptor cross-linking at Burkitt's lymphoma cell surfaces.
    Holder MJ; Chamba A; Hardie DL; Deans JP; Gordon J
    Leuk Res; 2004 Nov; 28(11):1197-202. PubMed ID: 15380345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.
    Varano G; Raffel S; Sormani M; Zanardi F; Lonardi S; Zasada C; Perucho L; Petrocelli V; Haake A; Lee AK; Bugatti M; Paul U; Van Anken E; Pasqualucci L; Rabadan R; Siebert R; Kempa S; Ponzoni M; Facchetti F; Rajewsky K; Casola S
    Nature; 2017 Jun; 546(7657):302-306. PubMed ID: 28562582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.
    Corso J; Pan KT; Walter R; Doebele C; Mohr S; Bohnenberger H; Ströbel P; Lenz C; Slabicki M; Hüllein J; Comoglio F; Rieger MA; Zenz T; Wienands J; Engelke M; Serve H; Urlaub H; Oellerich T
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5688-93. PubMed ID: 27155012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
    Mrdenovic S; Zhang Y; Wang R; Yin L; Chu GC; Yin L; Lewis M; Heffer M; Zhau HE; Chung LWK
    Cancer; 2019 Jul; 125(13):2222-2232. PubMed ID: 30840322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.
    Liu XY; Pop LM; Tsai L; Pop IV; Vitetta ES
    Int J Cancer; 2011 Jul; 129(2):497-506. PubMed ID: 20878959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.
    Zhang L; Jiang Y; Zheng Y; Zeng Y; Yang Z; Huang G; Liu D; Gao M; Shen X; Wu G; Yan X; He F
    Leukemia; 2011 Feb; 25(2):331-40. PubMed ID: 21102426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entry of B cell antigen receptor and antigen into class II peptide-loading compartment is independent of receptor cross-linking.
    Song W; Cho H; Cheng P; Pierce SK
    J Immunol; 1995 Nov; 155(9):4255-63. PubMed ID: 7594583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
    Chang CH; Wang Y; Gupta P; Goldenberg DM
    MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
    Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
    Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
    Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
    Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
    Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
    J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.